Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous ...

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...

An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and ...

At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the ...